Mankind Pharma Ltd (NSE:MANKIND) — Stock Price
Mankind Pharma Ltd (NSE:MANKIND) is currently trading at Rs2438.00 INR, down 0.73% today. Over the past 52 weeks, shares have ranged between Rs1927.40 and Rs2660.60. This page tracks Mankind Pharma Ltd's live share price on the NSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see MANKIND stock market capitalisation.
Mankind Pharma Ltd (MANKIND) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Mankind Pharma Ltd's daily closing share price and trading volume on the NSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Mankind Pharma Ltd Income Statement — Revenue, Profit & Earnings by Year
Mankind Pharma Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | Rs122.07 Billion | Rs103.35 Billion | Rs87.43 Billion | Rs77.82 Billion | Rs62.14 Billion |
| Cost of Revenue | Rs34.89 Billion | Rs33.21 Billion | Rs53.54 Billion | Rs24.70 Billion | Rs18.25 Billion |
| Gross Profit | Rs87.18 Billion | Rs70.14 Billion | Rs33.88 Billion | Rs53.12 Billion | Rs43.89 Billion |
| Research & Development | Rs2.32 Billion | Rs254.54 Million | Rs254.54 Million | Rs20.39 Million | Rs123.71 Million |
| SG&A | Rs27.18 Billion | Rs22.98 Billion | Rs10.95 Billion | Rs1.25 Billion | Rs748.78 Million |
| Total Operating Expenses | Rs26.92 Billion | Rs29.27 Billion | Rs17.70 Billion | Rs34.33 Billion | Rs27.83 Billion |
| Operating Income | Rs60.26 Billion | Rs40.87 Billion | Rs16.18 Billion | Rs18.61 Billion | Rs16.06 Billion |
| EBITDA | Rs30.18 Billion | Rs28.09 Billion | Rs20.27 Billion | Rs21.47 Billion | Rs18.17 Billion |
| EBIT | Rs23.97 Billion | Rs24.11 Billion | Rs17.01 Billion | Rs19.80 Billion | Rs16.98 Billion |
| Interest Expense | Rs4.29 Billion | Rs278.20 Million | Rs419.88 Million | Rs202.31 Million | Rs177.16 Million |
| Income Before Tax | Rs25.16 Billion | Rs23.99 Billion | Rs16.71 Billion | Rs19.75 Billion | Rs16.92 Billion |
| Income Tax Expense | Rs5.10 Billion | Rs4.58 Billion | Rs3.62 Billion | Rs5.22 Billion | Rs3.99 Billion |
| Net Income | Rs19.91 Billion | Rs19.13 Billion | Rs12.82 Billion | Rs14.33 Billion | Rs12.65 Billion |
Mankind Pharma Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Mankind Pharma Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | Rs277.60 Billion | Rs119.63 Billion | Rs97.15 Billion | Rs91.48 Billion | Rs63.73 Billion |
| Total Current Assets | Rs69.88 Billion | Rs65.68 Billion | Rs43.28 Billion | Rs44.07 Billion | Rs39.07 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | Rs16.91 Billion | Rs7.46 Billion | Rs12.24 Billion | Rs9.77 Billion | Rs18.37 Billion |
| Net Receivables | Rs15.38 Billion | Rs8.48 Billion | Rs6.06 Billion | Rs4.27 Billion | Rs4.24 Billion |
| Inventory | Rs20.94 Billion | Rs15.53 Billion | Rs14.98 Billion | Rs17.60 Billion | Rs11.84 Billion |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | Rs64.93 Billion | Rs200.22 Million | Rs200.22 Million | Rs204.42 Million | Rs204.42 Million |
| Total Liabilities | Rs131.91 Billion | Rs23.87 Billion | Rs20.67 Billion | Rs28.31 Billion | Rs15.10 Billion |
| Total Current Liabilities | Rs56.64 Billion | Rs21.20 Billion | Rs18.63 Billion | Rs26.23 Billion | Rs13.53 Billion |
| Long-term Debt | — | — | — | Rs491.94 Million | Rs576.70 Million |
| Net Debt | Rs79.57 Billion | Rs-1.75 Billion | Rs-1.34 Billion | Rs5.71 Billion | Rs734.77 Million |
| Total Stockholder Equity | Rs143.32 Billion | Rs93.63 Billion | Rs74.35 Billion | Rs61.55 Billion | Rs47.22 Billion |
| Retained Earnings | Rs119.07 Billion | Rs99.19 Billion | Rs80.12 Billion | Rs67.35 Billion | Rs53.04 Billion |
Mankind Pharma Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Mankind Pharma Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | Rs24.13 Billion | Rs21.52 Billion | Rs18.13 Billion | Rs9.20 Billion | Rs11.37 Billion |
| Capital Expenditures | Rs4.61 Billion | Rs3.82 Billion | Rs8.32 Billion | Rs23.46 Billion | Rs3.12 Billion |
| Free Cash Flow | Rs19.53 Billion | Rs17.70 Billion | Rs9.53 Billion | Rs-14.26 Billion | Rs8.25 Billion |
| Investing Cash Flow | Rs-126.92 Billion | Rs-20.82 Billion | Rs-10.54 Billion | Rs-13.69 Billion | Rs-12.22 Billion |
| Financing Cash Flow | Rs102.33 Billion | Rs52.66 Million | Rs-7.40 Billion | Rs6.05 Billion | Rs-78.11 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | Rs266.40 Million | Rs231.86 Million | Rs591.00K | — | — |
| Depreciation | Rs6.21 Billion | Rs3.98 Billion | Rs3.26 Billion | Rs1.67 Billion | Rs1.19 Billion |
| Change in Cash | Rs218.72 Million | Rs771.87 Million | Rs217.60 Million | Rs1.56 Billion | Rs-924.03 Million |
Mankind Pharma Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Mankind Pharma Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Feb 03, 2026 | 11.99 | 11.93 | +0.50% |
| Nov 06, 2025 | 12.38 | 12.43 | -0.40% |
| Jun 30, 2025 | 10.60 | 11.12 | -4.65% |
| May 21, 2025 | 10.29 | 8.60 | +19.65% |
| Jan 23, 2025 | 9.44 | 11.64 | -18.90% |
| Nov 05, 2024 | 16.28 | 14.65 | +11.13% |
| Jun 30, 2024 | 13.37 | 14.23 | -6.01% |
| May 15, 2024 | 11.74 | 9.60 | +22.29% |